Brain Cancer. The effectiveness of cannabinoids in fighting glioblastoma multiforme (GBM), a form of brain cancer that is highly resistant to current treatments, has been demonstrated in numerous preclinical studies. New research shows that a combination of THC, CBD, and temozolomide (TMZ) “remarkably reduces the growth of glioma.” The study revealed tumor growth is inhibited in part through “the stimulation of autophagy-mediated apoptosis,” the biologic degradation of cells that leads to them dying off. The Spanish researchers conclude that “the combined administration of TMZ and cannabinoids could be therapeutically exploited for the management of GBM.”

Torres S, et al. 2011. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011 Jan;10(1):90-103.

Oral Cancer. Medical researchers at the University of California report cannabinoids alleviate oral cancer pain and slow the spread of the disease both in vitro and in vivo. They also identified CB1 and CB2 cannabinoid receptors in human oral cancer cells. They suggest the endocannabinoid system may play “a direct role” in pain and proliferation. Noting proliferation of cancer cells was “significantly attenuated in a dose-dependent manner” by cannabinoids, they conclude “the systemic administration” of cannabinoids “may reduce morbidity and mortality of oral cancer.”

Saghafi N, et al. 2011. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neurosci Lett. 488(3):247-51.

Gastric Cancer. Previous studies have shown cannabinoids significantly decrease the spread of gastric cancer tumors and kill off malignant cells. South Korean researchers have recently discovered some of the biologic mechanisms for those tumor-fighting properties. The new research on cellular mediators indicates cannabinoids play a role in halting cell cycles that cause the cancer to spread.

Park JM, et al. 2011. Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. J Cell Biochem. Feb 10.

Leave a Reply

Your email address will not be published. Required fields are marked *